Xiaodong Lu
- Department of Urology
Instructor
- (404) 778-6809
Overview
Xiaodong Lu completed his PhD in Biochemistry and Molecular Biology at Xiamen University in Fujian, China (2015) and his Postdoctoral Research Fellowship in the Department of Medicine at Northwestern University Feinberg School of Medicine (2020). Prior to joining the faculty at Emory in 2023, Dr. Lu held a position as a Research Associate in the Department of Medicine, Northwestern University Feinberg School of Medicine.
His articles have been published in a number of leading journals including Nature Genetics, Molecular Cell, and the Journal of Clinical Investigation. Dr. Lu will develop research interests in cancer biology with special emphasis in prostate and genitourinary cancer.
He will serve as an instructor in the Department of Urology.
Academic Appointment
- Instructor, Department of Urology, Emory University School of Medicine
Education
Degrees
- PhD from Xiamen University
Research
Publications
-
Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth.
J Clin Invest Volume: 133
08/01/2023 Authors: Gritsina G; Fong K-W; Lu X; Lin Z; Xie W; Agarwal S; Lin D; Schiltz GE; Beltran H; Corey E -
Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer.
Oncogene Volume: 42 Page(s): 2126 - 2138
06/01/2023 Authors: Lin Z; Agarwal S; Tan S; Shi H; Lu X; Tao Z; Dong X; Wu X; Zhao JC; Yu J -
PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing.
Mol Cell Volume: 82 Page(s): 4611 - 4626.e7
12/15/2022 Authors: Fong K-W; Zhao JC; Lu X; Kim J; Piunti A; Shilatifard A; Yu J -
FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
Oncogene Volume: 41 Page(s): 4259 - 4270
09/01/2022 Authors: Wang X; Brea L; Lu X; Gritsina G; Park SH; Xie W; Zhao JC; Yu J -
HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer.
Nat Genet Volume: 54 Page(s): 670 - 683
05/01/2022 Authors: Lu X; Fong K-W; Gritsina G; Wang F; Baca SC; Brea LT; Berchuck JE; Spisak S; Ross J; Morrissey C -
Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer.
Sci Adv Volume: 7
04/01/2021 Authors: Park SH; Fong K-W; Kim J; Wang F; Lu X; Lee Y; Brea LT; Wadosky K; Guo C; Abdulkadir SA -
Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression.
Cell Res Volume: 29 Page(s): 773 - 775
09/01/2019 Authors: Xu B; Song B; Lu X; Kim J; Hu M; Zhao JC; Yu J -
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
J Clin Invest Volume: 129 Page(s): 3924 - 3940
07/01/2019 Authors: Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X -
Targeting FOXA1-mediated repression of TGF- signaling suppresses castration-resistant prostate cancer progression.
J Clin Invest Volume: 129 Page(s): 569 - 582
02/01/2019 Authors: Song B; Park S-H; Zhao JC; Fong K-W; Li S; Lee Y; Yang YA; Sridhar S; Lu X; Abdulkadir SA -
Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator.
Cell Rep Volume: 25 Page(s): 2808 - 2820.e4
12/04/2018 Authors: Kim J; Lee Y; Lu X; Song B; Fong K-W; Cao Q; Licht JD; Zhao JC; Yu J